Abstract
Historically blood transfusion and organ transplantation were the first personalized therapies as they were matched to the individuals. Some cell therapies that use the patient’s own cells are considered to be personalized medicines particularly vaccines prepared from the individual patient’s tumor cells. More recently recombinant human proteins have been used to provide individualization of therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dhiman N, Ovsyannikova IG, Vierkant RA et al (2008) Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26:1731–1736
Jain KK (1998b) Textbook of gene therapy. Hogrefe & Huber, Göttingen-Seattle.
Jain KK (2009h) Cell therapy: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.
Jain KK (2009i) Gene therapy: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.
Jain KK (2009j) RNAi: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.
Li Z, Qiao Y, Liu B et al (2005) Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 11:4460–4468
Poland GA, Ovsyannikova IG, Jacobson RM (2008) Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 8:1659–1667
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jain, K.K. (2009). Personalized Biological Therapies. In: Textbook of Personalized Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0769-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0769-1_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0768-4
Online ISBN: 978-1-4419-0769-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)